Form 4: Natera Executive Sells Shares for Tax Obligations Under Pre-Arranged Plan

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,206 shares of common stock to cover tax withholding related to RSU vesting, as part of a Rule 10b5-1 plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported a sale of common stock.
• The transaction involved the disposition of 2,206 shares of Natera common stock.
• The shares were sold at a price of $139.8083 per share.
• The sale was executed on July 28, 2025.
• Following this transaction, Solomon Moshkevich beneficially owns 126,059 shares of Natera common stock.
• The sale was made to satisfy tax withholding and remittance obligations associated with the vesting of Restricted Stock Units (RSUs).
• The transaction was conducted pursuant to a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale is a routine, non-discretionary transaction to cover tax liabilities from RSU vesting, which is a common occurrence for executives and does not typically reflect a change in management's confidence in the company's future.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction, specifically a non-discretionary sale of shares by a company executive to cover tax obligations arising from RSU vesting. Such transactions are common across industries and are typically pre-scheduled under Rule 10b5-1 plans to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's outlook or a significant divestment.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale by an executive to cover tax obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of insider sale is not indicative of a change in the executive's confidence in the company's prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should 'hold' and consider broader company fundamentals and market conditions.

Keywords

Natera, NTRA, Solomon Moshkevich, Insider Trading, Stock Sale, Form 4, RSU, Tax Withholding, 10b5-1 Plan, Clinical Diagnostics